Strict control of atherogenic cholesterol and cardiovascular disease prevention

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Low-density lipoprotein (LDL) cholesterol is a confirmed causal agent of arteriosclerosis.
• Extensive clinical trials support the efficacy of lipid-lowering therapies.

Purpose of the Study:

• To review the scientific evidence supporting lipid-lowering therapy for cardiovascular risk reduction.
• To highlight the mechanisms of action for effective LDL cholesterol-lowering drugs.

Main Methods:

• Analysis of high-quality clinical trials (randomized, controlled, double-blind, placebo-controlled).
• Review of pharmacological mechanisms targeting LDL cholesterol reduction.

Main Results:

• Lipid-lowering therapy reduces cardiovascular complications with minimal side effects, even at LDL cholesterol levels of 30 mg/dL.
• Drugs like statins, ezetimibe, and PCSK9 inhibitors effectively lower circulating LDL cholesterol by enhancing LDL receptor activity.

Conclusions:

• Sustained reduction of LDL cholesterol over time enhances cardiovascular protection.
• Improved LDL cholesterol control in high-risk patients is crucial for further reducing cardiovascular morbidity and mortality.